Comorbidity of acne and disorders of intestinal microbiocenosis: theoretical and real

Cover Page

Cite item

Full Text

Abstract

Improving diagnostic capabilities leads to a significant increase in clinical situations, when it is already difficult to talk about the presence of a single disease in a patient - currently, in most clinical cases, there is a combined or concomitant pathology. The review considers the issues of acne comorbidity and disorders of intestinal microbiocenosis in theoretical and practical aspects. In 1930, the gastroenterological mechanism of the relationship between emotional and nervous conditions (anxiety, depression) and skin diseases (such as acne) was formulated and designated as the "gut-brain-skin axis". For several decades, this hypothesis was dormant. However, reviews of the last decade provide numerous facts that indirectly indicate the validity of the “intestine-brain-skin” hypothesis, and are the basis for the theoretical comorbidity of acne and intestinal microbiocenosis disorders. in real clinical practice, this relationship does not seem so obvious and requires further study of the mechanisms and effects of oral probiotics in acne.

About the authors

Dmitry I. Trukhan

Omsk State Medical University

Email: dmitry_trukhan@mail.ru
д-р мед. наук, доц., проф. каф. поликлинической терапии и внутренних болезней Omsk, Russia

References

  1. Van den Akker M, Buntinx F, Metsemakers JF et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998; 51 (5): 367-75. doi: 10.1016/s0895-4356(97)00306-5
  2. Лазебник Л.Б., Конев Ю.В. Исторические особенности и семантические трудности использования терминов, обозначающих множественность заболеваний у одного больного. Экспе-рим. и клин. гастроэнтерология. 2018; 6 (154): 4-9. https://www.nogr.org/jour/article/view/629/624
  3. Трухан Д.И. Нестероидные противовоспалительные препараты сквозь призму коморбидности и лекарственной безопасности: в фокусе - амтолметин гуацил. Consilium Medicum. 2015; 17 (2): 27-33. doi: 10.26442/2075-1753_2015.2.27-33
  4. Трухан Д.И., Лебедев О.И., Сулимов А.Ф., Трухан Л.Ю. Изменение органа зрения, кожи и слизистых оболочек при заболеваниях кишечника. Терапия. 2018; 2 (20): 34-40. https://www.elibrary.ru/item.asp?id=32706743
  5. Федеральные клинические рекомендации по ведению больных акне. 2013. http://www.minzd-ravrb.ru/minzdrav/docs/akne.pdf
  6. Акне. Клинические рекомендации 2016. https://medi.ru/klinicheskie-rekomendatsii/akne_13842/
  7. Клинические рекомендации. Акне вульгарные. Проект. Российское общество дерматовенерологов и косметологов. 2020. http://www.rodv.ru/events/274.html
  8. Nast A, Dreno B, Bettoli V et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol 2016; 30 (8): 1261-8. doi: 10.1111/jdv.13776
  9. Приказ от 11.12.2007 №750 «Об утверждении стандарта медицинской помощи больным с акне». http://docs.cntd.ru/document/902077901
  10. Bowe WP, Logan AC. Acne vulgaris, probiotics and the gut-brain-skin axis - back to the future? Gut Pathog 2011; 3 (1): 1. doi: 10.1186/1757-4749-3-1
  11. Харитонова Л.А., Григорьев К.И., Борзакова С.Н. Микробиота человека: как новая научная парадигма меняет медицинскую практику. Эксперим. и клин. гастроэнтерология. 2019; 161 (1): 55-63. doi: 10.31146/1682-8658-ecg-161 -1 -55-63
  12. Юдина Ю.В., Корсунский А.А., Аминова А.И. и др. Микробиота кишечника как отдельная система организма. Доказательная гастроэнтерология. 2019; 8 (4-5): 36-43. doi: 10.17116/dokgastro2019804-05136
  13. Кайбышева В.О., Жарова М.Е., Филимендикова К.Ю., Никонов Е.Л. Микробиом человека: возрастные изменения и функции. Доказательная гастроэнтерология. 2020; 9 (2): 42-55. doi: 10.17116/dokgastro2020902142
  14. Комарова О.Н., Хавкин А.И. Взаимосвязь стресса, иммунитета и кишечной микробиоты. Педиатрическая фармакология. 2020; 17 (1): 18-24. doi: 10.15690/pf.v17i1.2078
  15. Bowe W, Patel NB, Logan AC. Acne vulgaris, probiotics and the gut-brain-skin axis: from anecdote to translational medicine. Benef Microbes 2014; 5 (2): 185-99. doi: 10.3920/BM2012.0060
  16. Forsythe P Kunze W, Bienenstock J. Moody microbes or fecal phrenology: what do we know about the microbiota-gut-brain axis? BMC Med 2016; 14: 58-72. doi: 10.1186/s12916-016-0604-8
  17. Clark A, Mach N. Exercise-induced stress behavior, gut-microbiota-brain axis and diet: a systematic review for athletes. J Int Soc Sports Nutr 2016; 13: 43. doi: 10.1186/s12970-016-0155-6
  18. Clark AK, Haas KN, Sivamani RK. Edible Plants and Their Influence on the Gut Microbiome and Acne. Int J Mol Sci 2017; 18 (5): 1070. doi: 10.3390/ijms18051070
  19. Musthaq S, Mazuy A, Jakus J. The microbiome in dermatology. Clin Dermatol 2018; 36 (3): 390-8. doi: 10.1016/j.clindermatol.2018.03.012
  20. Salem I, Ramser A, Isham N, Ghannoum MA. The Gut Microbiome as a Major Regulator of the GutSkin Axis. Front Microbiol 2018; 9: 1459. doi: 10.3389/fmicb.2018.01459
  21. Deng Y, Wang H, Zhou J et al. Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls. Acta Derm Venereol 2018; 98 (8): 783-90. doi: 10.2340/000155552968
  22. Lee YB, Byun EJ, Kim HS. Potential Role of the Microbiome in Acne: A Comprehensive Review. J Clin Med 2019; 8 (7): 987. doi: 10.3390/jcm8070987
  23. Balato A, Cacciapuoti S, Di Caprio R et al. Human Microbiome: Composition and Role in Inflammatory Skin Diseases. Arch Immunol Ther Exp (Warsz) 2019; 67 (1): 1-18. doi: 10.1007/s00005-018-0528-4
  24. Goodarzi A, Mozafarpoor S, Bodaghabadi M, Mohamadi M. The potential of probiotics for treating acne vulgaris: A review of literature on acne and microbiota. Dermatol Ther 2020; 33 (3): e13279. doi: 10.1111/dth.13279
  25. Lu CY Hsieh MS, Wei KC et al. Gastrointestinal involvement of primary skin diseases. J Eur Acad Dermatol Venereol 2020. doi: 10.1111/jdv.16676
  26. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut 2006; 55 (10): 1512-20. doi: 10.1136/gut.2005.085373
  27. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 11: 799-809. doi: 10.1038/nri2653
  28. Odenwald MA, Turner JR. Intestinal permeability defects: Is it time to treat? Clin Gastroenterol Hepatol 2013; 11 (9): 1075-83. doi: 10.1016/j.cgh.2013.07.001
  29. Graziani C, Talocco C, De Sire R et al. Intestinal Permeability in Physiological and Pathological Conditions: Major Determinants and Assessment Modalities. Eur Rev Med Pharmacol Sci 2019; 23 (2): 795-810. doi: 10.26355/eurrev_201901_1689
  30. Sturgeon C, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers 2016; 4: e1251384. doi: 10.1080/21688370.2016.1251384
  31. Chang J, Leong RW, Wasinger VC et al. Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing. Gastroenterology 2017; 153: 723-31. doi: 10.1053/j.gastro.2017.05.056
  32. Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis 2016; 1 (3): 135-45. doi: 10.1159/000447252
  33. Eutamene H, Beaufrand C, Harkat C, Theodorou V. The role of mucoprotectants in the management of gastrointestinal disorders. Expert Rev Gastroenterol Hepatol 2018; 12 (1): 83-90. doi: 10.1080/17474124.2018.1378573
  34. Drossman DA, Hasler WL. Rome IV - Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology 2016; 150 (6): 1257-61. doi: 10.1053/j.gastro.2016.03.035
  35. Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med 2017; 6 (11). doi: 10.3390/jcm6110099
  36. Demirba? A, Elmas OF. The relationship between acne vulgaris and irritable bowel syndrome: A preliminary study. J Cosmet Dermatol 2020. doi: 10.1111/jocd.13481
  37. Baquerizo Nole KL, Yim E, Keri JE. Probiotics and prebiotics in dermatology. J Am Acad Dermatol 2014; 71 (4): 814-21. doi: 10.1016/j.jaad.2014.04.050
  38. Kumar S, Mahajan BB, Kamra N. Future perspective of probiotics in dermatology: an old wine in new bottle. Dermatol Online J 2014; 20 (9): 13030/qt8br333fc
  39. Fuchs-Tarlovsky V, Marquez-Barba MF, Sriram K. Probiotics in dermatologic practice. Nutrition 2016; 32 (3): 289-95. doi: 10.1016/j.nut.2015.09.001
  40. Fabbrocini G, Bertona M, Picazo 0 et al. Supplementation with Lactobacillus rhamnosus SP1 normalises skin expression of genes implicated in insulin signalling and improves adult acne. Benef Microbes 2016; 7 (5): 625-30. doi: 10.3920/BM2016.0089
  41. Mottin VHM, Suyenaga ES. An approach on the potential use of probiotics in the treatment of skin conditions: acne and atopic dermatitis. Int J Dermatol 2018; 57 (12): 1425-32. doi: 10.1111/ijd.13972
  42. Trivedi MK, Bosanac SS, Sivamani RK, Larsen LN. Emerging Therapies for Acne Vulgaris. Am J Clin Dermatol 2018; 19 (4): 505-16. doi: 10.1007/s40257-018-0345-x
  43. Syzon OO, Dashko MO. Indicators of phagocytosis in women with acne during comprehensive treatment that included immunotherapy and probiotics. Wiad Lek 2018; 71 (1 Pt 2): 144-7. https://pub-med.ncbi.nlm.nih.gov/29602922/
  44. Rahmayani T, Putra IB, Jusuf NK. The Effect of Oral Probiotic on the Interleukin-10 Serum Levels of Acne Vulgaris. Open Access Maced J Med Sci 2019; 7 (19): 3249-52. doi: 10.3889/oamjms.2019.718
  45. Yu Y, Dunaway S, Champer J et al. Changing our microbiome: probiotics in dermatology. Br J Dermatol 2020; 182 (1): 39-46. doi: 10.1111/bjd.18088
  46. Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis 2016; 1 (3): 135-45. doi: 10.1159/000447252
  47. Otani K, Tanigawa T, Watanabe T et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion 2017; 95 (1): 22-8. doi: 10.1159/000452356
  48. Matysiak-Budnik T, Heyman M, Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther 2003; 18 (Suppl. 1): 55-62. doi: 10.1046/j.1365-2036.18.s1.6.x
  49. Ардатская М.Д., Бельмер С.В., Добрица В.П. и др. Дисбиоз (дисбактериоз) кишечника: современное состояние проблемы, комплексная диагностика и лечебная коррекция. Экспе-рим. и клин. гастроэнтерология. 2015; 5: 13-50. https://cyberleninka.ru/article/nZdisbioz-disbak-terioz-kishechnika-sovremennoe-sostoyanie-problemy-kompleksnaya-diagnostika-i-lechebnaya-korr ektsiya/viewer
  50. Тарасова Л.В., Трухан Д.И. Болезни кишечника. Клиника, диагностика и лечение. СПб.: СпецЛит, 2013. https://www.razym.ru/nauchmed/vnutri/321103-truhan-d-bolezni-kishechnika-kli-nika-diagnostika-i-lechenie-uchebnoe-posobie.html
  51. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М.: Практическая медицина, 2016. https://lettercan.at.ua/news/differencialnyj_diagnoz_osnovnykh_gastroehnterologicheskikh_sindro-mov_i_simptomov_trukhan_filimonov/2017-09-10-306
  52. Трухан Д.И., Голошубина В.В., Иванова Д.С. Актуальные вопросы диагностики и лечения синдрома раздраженного кишечника. Мед. совет. 2018; 21: 110-6. doi: 10.21518/2079-701X-2018-21-110-116
  53. Patel M, Bowe WP, Heughebaert C, Shalita AR. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: A review. J Drugs Dermatol 2010; 9: 655-64.
  54. Зайнуллина О.Н., Хисматуллина З.Р., Хайретдинова Т.Б. Коррекция дисбиотических нарушений кишечной микрофлоры у больных с акне. Эксперим. и клин. гастроэнтерология. 2012; 1: 38-42. https://pubmed.ncbi.nlm.nih.gov/22808777/
  55. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6-30. doi: 10.1136/gutjnl-2016-312288
  56. Well D. Acne vulgaris: A review of causes and treatment options. Nurse Pract 2013; 38 (10): 22-31; quiz 32. doi: 10.1097/01. NPR.0000434089.88606.70
  57. Chernyshov PV, Zouboulis CC, Tomas-Aragones L et al. Quality of life measurement in acne. Position Paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2018; 32 (2): 194-208. doi: 10.1111/jdv.14585
  58. Львов А.Н., Корнят М.С., Игошина А.В., Назаренко А.Р. Перспективы в терапии акне: аналитический обзор. Клин. дерматология и венерология. 2019; 18 (2): 115-28. https://doi.org/10.17116/klinderma201918021T15
  59. Jung GW, Tse JE, Guiha I, Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg 2013; 17 (2): 114-22. doi: 10.2310/7750.2012.12026
  60. Kucharska A, Szmurlo A, Sinska B. Significance of diet in treated and untreated acne vulgaris. Po-stepy Dermatol Alergol 2016; 33 (2): 81-6. doi: 10.5114/ada.2016.59146
  61. Shinohara K, Ohashi Y, Kawasumi K et al. Effect of apple intake on fecal microbiota and metabolites in humans. Anaerobe 2010; 16: 510-5. doi: 10.1016/j.anaerobe.2010.03.005
  62. Palm NW, de Zoete MR, Flavell RA. Immune-microbiota interactions in health and disease. Clin Immunol 2015; 159: 122-7. doi: 10.1016/j.clim.2015.05.014
  63. Sonnenburg JL, Backhed F Diet-microbiota interactions as moderators of human metabolism. Nature 2016; 535: 56-64. doi: 10.1038/nature18846
  64. Song H, Yoo Y Hwang J et al. Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J Allergy Clin Immunol 2016; 137: 852-60. doi: 10.1016/j.jaci.2015.08.021
  65. Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-81. doi: 10.2337/db07-1403
  66. Martinez-Medina M, Denizot J, Dreux N et al. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut 2014; 63: 116-24. doi: 10.1136/gutjnl-2012-304119
  67. Morales P, Fujio S, Navarrete P et al. Impact of dietary lipids on colonic function and microbiota: an experimental approach involving orlistatinduced fat malabsorption in human volunteers. Clin Transl Gastroenterol 2016; 7 (4): e161. doi: 10.1038/ctg.2016.20

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies